Changes in Ptf V1 before and after Using Recombinant Human Brain Natriuretic Peptide and Their Clinical Significance in Patients with Acute Heart Failure

FANG Ding-fen,ZHANG Deng-qing,LI Wei-hua
2011-01-01
Abstract:ObjectiveTo observe the changes in P terminal force in lead V1(Ptf V1) before and after using recombinant human brain natriuretic peptide(BNP) by bedside ECG monitoring and to investigate their clinical significance in patients with acute heart failure.MethodsThe Ptf V1 was measured by bedside ECG monitoring in 407 patients with acute heart failure(NYHA class Ⅲ-Ⅳ),including 197 patients with coronary heart disease,110 patients with hypertensive heart disease,55 patients with cardiomyopathy and 45 patients with valvular heart disease.These patients were treated with intravenous pulse of 1.5 μg·kg-1recombinant human BNP,followed by continuous intravenous infusion of 0.007 5 μg·kg-1·min-1recombinant human BNP.The course of treatment was 5-7 days(18 hours per day).After cardiac function was improved to NYHA class Ⅰ,the changes in Ptf V1 were observed and the parameters,including ejection fraction(EF),cardiac index(CI),early peak flow velocity,late peak flow velocity(A) and ratio of E peak to A peak(E/A) were determined by GE vivi7 ultrasound system.ResultsAfter treatment with recombinant human BNP,EF,CI and E/A were significantly improved and negative value of Ptf V1 was significantly decreased(P<0.05 or <0.01).ConclusionThe observation of changes in Ptf V1 has clinical and practical significance for assessing the effects of recombinant human BNP on acute heart failure.
What problem does this paper attempt to address?